| Year |
Citation |
Score |
| 2020 |
Chaudhary S, Kwak EL, Hwang KL, Lennerz JK, Corcoran RB, Heist RS, Russo AL, Parikh A, Borger DR, Blaszkowsky LS, Faris JE, Murphy JE, Azzoli CG, Roeland EJ, Goyal L, et al. Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers. The Oncologist. PMID 32820577 DOI: 10.1634/Theoncologist.2020-0274 |
0.386 |
|
| 2020 |
Shih DJH, Nayyar N, Bihun I, Dagogo-Jack I, Gill CM, Aquilanti E, Bertalan M, Kaplan A, D'Andrea MR, Chukwueke U, Ippen FM, Alvarez-Breckenridge C, Camarda ND, Lastrapes M, McCabe D, ... ... Borger DR, et al. Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma. Nature Genetics. PMID 32203465 DOI: 10.1038/S41588-020-0592-7 |
0.301 |
|
| 2019 |
Tanaka S, Batchelor TT, Iafrate AJ, Dias-Santagata D, Borger DR, Ellisen LW, Yang D, Louis DN, Cahill DP, Chi AS. PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma. Acta Neuropathologica Communications. 7: 66. PMID 31036078 DOI: 10.1186/S40478-019-0720-8 |
0.442 |
|
| 2019 |
Voss MH, Hierro C, Heist RS, Cleary JM, Meric-Bernstam F, Tabernero J, Janku F, Gandhi L, Iafrate AJ, Borger DR, Ishii N, Hu Y, Kirpicheva Y, Nicolas-Metral V, Pokorska-Bocci A, et al. A Phase I, Multicenter, Dose-Escalation Study of the Oral Selective FGFR inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30745300 DOI: 10.1158/1078-0432.Ccr-18-1959 |
0.308 |
|
| 2019 |
Nayyar N, White MD, Gill CM, Lastrapes M, Bertalan M, Kaplan A, D'Andrea MR, Bihun I, Kaneb A, Dietrich J, Ferry JA, Martinez-Lage M, Giobbie-Hurder A, Borger DR, Rodriguez FJ, et al. L265P mutation and loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas. Blood Advances. 3: 375-383. PMID 30723112 DOI: 10.1182/Bloodadvances.2018027672 |
0.388 |
|
| 2018 |
Brunner AM, Neuberg DS, Wander SA, Sadrzadeh H, Ballen KK, Amrein PC, Attar E, Hobbs GS, Chen YB, Perry A, Connolly C, Joseph C, Burke M, Ramos A, Galinsky I, ... ... Borger DR, et al. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. Cancer. PMID 30422308 DOI: 10.1002/Cncr.31729 |
0.411 |
|
| 2018 |
Mitra D, Clark JW, Shih HA, Oh KS, Brastianos PK, Wo JY, Strickland MR, Curry WT, Parikh AR, Corcoran RB, Ryan DP, Iafrate AJ, Borger DR, Lennerz JK, Hong TS. Enrichment of Amplification in Brain Metastases from Primary Gastrointestinal Malignancies. The Oncologist. PMID 30373904 DOI: 10.1634/Theoncologist.2018-0152 |
0.327 |
|
| 2018 |
Kamran SC, Clark JW, Zheng H, Borger DR, Blaszkowsky LS, Allen JN, Kwak EL, Wo JY, Parikh AR, Nipp RD, Murphy JE, Goyal L, Zhu AX, Iafrate AJ, Corcoran RB, et al. Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis. Cancer Medicine. PMID 29771009 DOI: 10.1002/Cam4.1558 |
0.443 |
|
| 2018 |
Hong TS, Hwang KL, Clark JW, Lennerz JK, Shui A, Zheng H, Szymonifka J, Corcoran RB, Heist RS, Russo AL, Parikh AR, Borger DR, Blaszkowsky LS, Faris JE, Murphy JE, et al. MET-amplification (MET-amp) in relation to aggressive biology in esophagogastric cancer (EGC): An analysis of clinical outcomes of MET-amp vs non-MET-amp EGC. Journal of Clinical Oncology. 36: 74-74. DOI: 10.1200/Jco.2018.36.4_Suppl.74 |
0.448 |
|
| 2018 |
Hong TS, Wo JY, Ryan DP, Zheng H, Borger DR, Kwak EL, Allen JN, Berger DL, Rattner DW, Cusack JC, Gemma AJ, Mamon HJ, Eyler CE, Shellito PC, Zhu AX, et al. Phase Ib study of neoadjuvant chemoradiation (CRT) with midostaurin, 5-fluorouracil (5-FU) and radiation (XRT) for locally advanced rectal cancer: Sensitization of RAS mutant tumors. Journal of Clinical Oncology. 36: e15674-e15674. DOI: 10.1200/Jco.2018.36.15_Suppl.E15674 |
0.427 |
|
| 2018 |
White M, Brastianos PK, Batchelor T, Nayyar N, Gill C, Lastrapes M, Bertalan M, Kaplan A, D'Andrea M, Bihun I, Kaneb A, Dietrich J, Ferry J, Alvarez MM, Giobbie-Hurder A, ... Borger DR, et al. MYD88 L265P mutation and CDKN2A loss as early mutational events in primary central nervous system lymphomas. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E14041 |
0.376 |
|
| 2018 |
Mertz JA, Blum KA, Younes A, Abramson JS, Maris MB, Flinn IW, Goy A, Borger DR, Cooper MR, Sims RJ. Abstract 3674: Pharmacodynamic assessment in whole blood for the BET bromodomain inhibitor CPI-0610 of target engagement in patients with progressive lymphoma Cancer Research. 78: 3674-3674. DOI: 10.1158/1538-7445.Am2018-3674 |
0.323 |
|
| 2018 |
Ramos A, Fortin S, Melchert V, Jenkins D, Growdon W, Borger D. Abstract 1687: Checkpoint inhibitor signatures across endometrial cancer histologies Immunology. DOI: 10.1158/1538-7445.Am2018-1687 |
0.329 |
|
| 2018 |
Strickland M, Bertalan M, Kuter B, Juratli T, Melchert V, Higgins N, Toups M, Kaplan A, Bihun I, Nayyar N, Martinez-Lage M, Borger D, Shih H, Hong T, Brastianos P. CMET-15. WHOLE EXOME SEQUENCING OF BRAIN METASTASES FROM COLORECTAL PRIMARY CANCERS REVEALS CLINICALLY ACTIONABLE MUTATIONS Neuro-Oncology. 20: vi56-vi56. DOI: 10.1093/Neuonc/Noy148.227 |
0.404 |
|
| 2017 |
Reyes S, Horick N, Clark J, Murphy J, Blaszkowsky L, Allen J, Ryan DP, Hong T, Wo J, Nipp R, Parikh A, Faris J, Kwak E, Galway A, Knowles M, ... ... Borger D, et al. Frequency and impact of tumor genotyping in clinical practice of patients with advanced biliary tract cancers (ABTCs). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28: iii145-iii146. PMID 32135779 DOI: 10.1093/Annonc/Mdx262.020 |
0.363 |
|
| 2017 |
Arnason T, Borger DR, Corless C, Hagen C, Iafrate AJ, Makhlouf H, Misdraji J, Sapp H, Tsui WM, Wanless IR, Zuluaga Toro T, Lauwers GY. Biliary Adenofibroma of Liver: Morphology, Tumor Genetics, and Outcomes in 6 Cases. The American Journal of Surgical Pathology. PMID 28266931 DOI: 10.1097/Pas.0000000000000773 |
0.379 |
|
| 2017 |
Goyal L, Zheng H, Yurgelun MB, Abrams TA, Allen JN, Cleary JM, Knowles M, Regan E, Reardon A, Khachatryan A, Jain RK, Nardi V, Borger DR, Duda DG, Zhu AX. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Cancer. PMID 28192597 DOI: 10.1002/Cncr.30571 |
0.314 |
|
| 2017 |
Bao Y, Baig A, Wang Y, Iafrate AJ, Chen C, Borger DR. Abstract 740: Rapid detection of IDH1/2 mutations using RNaseH2 dependent, multiplex quantitative PCR Assays Cancer Research. 77: 740-740. DOI: 10.1158/1538-7445.Am2017-740 |
0.439 |
|
| 2016 |
Strickland MR, Gill CM, Nayyar N, D'Andrea MR, Thiede C, Juratli TA, Schackert G, Borger DR, Santagata S, Frosch MP, Cahill DP, Brastianos PK, Barker FG. Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas. Journal of Neurosurgery. 1-7. PMID 27885953 DOI: 10.3171/2016.8.Jns161076 |
0.435 |
|
| 2016 |
Heist RS, Sequist LV, Borger D, Gainor JF, Arellano RS, Le LP, Dias-Santagata D, Clark JW, Engelman JA, Shaw AT, Iafrate AJ. Acquired Resistance to Crizotinib in Non-small Cell Lung Cancer with MET exon 14 skipping. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 27343442 DOI: 10.1016/J.Jtho.2016.06.013 |
0.372 |
|
| 2016 |
Lennerz JK, van der Sloot KW, Le LP, Batten JM, Han JY, Fan KC, Siegel CA, Srivastava A, Park DY, Chen JH, Sands BE, Korzenik JR, Odze RD, Dias-Santagata D, Borger DR, et al. Colorectal cancer in Crohn's colitis is comparable to sporadic colorectal cancer. International Journal of Colorectal Disease. PMID 27026089 DOI: 10.1007/S00384-016-2574-X |
0.323 |
|
| 2016 |
Hernandez SF, Chisholm S, Borger D, Foster R, Rueda BR, Growdon WB. Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and PIK3CA mutation. Gynecologic Oncology. 141: 570-579. PMID 27017985 DOI: 10.1016/J.Ygyno.2016.03.027 |
0.439 |
|
| 2016 |
Penson RT, Sales E, Sullivan L, Borger DR, Krasner CN, Goodman AK, Del Carmen MG, Growdon WB, Schorge JO, Boruta DM, Castro CM, Dizon DS, Birrer MJ. A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer. Gynecologic Oncology. 141: 108-12. PMID 27016236 DOI: 10.1016/J.Ygyno.2016.02.032 |
0.508 |
|
| 2016 |
Fathi AT, Nahed BV, Wander SA, Iafrate AJ, Borger DR, Hu R, Thabet A, Cahill DP, Perry AM, Joseph CP, Muzikansky A, Chi AS. Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma. The Oncologist. PMID 26834160 DOI: 10.1634/Theoncologist.2015-0342 |
0.422 |
|
| 2016 |
Kalinsky K, Lee SJ, Rubin KM, Lawrence DP, Iafrate AJ, Borger DR, Margolin KA, Leitao MM, Koon HB, Tarhini AA, Pecora A, Cohen GI, Kuzel T, Kirkwood JM. A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and vulvovaginal melanomas: A trial of the ECOG-ACRIN Cancer Research Group (E2607). Journal of Clinical Oncology. 34: 9501-9501. DOI: 10.1200/Jco.2016.34.15_Suppl.9501 |
0.359 |
|
| 2016 |
Kamran SC, Clark JW, Borger DR, Szymonifka J, Kwak EL, Blaszkowsky LS, Murphy JE, Goyal L, Allen JN, Wo JY, Zhu AX, Iafrate AJ, Corcoran RB, Ryan DP, Hong TS. Clinical correlation with codon-specific mutations in metastatic colorectal cancer. Journal of Clinical Oncology. 34: 3596-3596. DOI: 10.1200/Jco.2016.34.15_Suppl.3596 |
0.424 |
|
| 2016 |
Hernandez SF, Chisholm S, Borger D, Foster R, Rueda BR, Growdon WB. Abstract 386: Addition of mTOR inhibition to HER2 blockade results in improved antitumor activity in a preclinical model of uterine serous carcinoma with HER2 gene amplification and a gain of function mutation in PIK3CA Cancer Research. 76: 386-386. DOI: 10.1158/1538-7445.Am2016-386 |
0.48 |
|
| 2015 |
Platt MY, Fathi AT, Borger DR, Brunner AM, Hasserjian RP, Balaj L, Lum A, Yip S, Dias-Santagata D, Zheng Z, Le LP, Graubert TA, Iafrate AJ, Nardi V. Detection of Dual IDH1 and IDH2 Mutations by Targeted Next-Generation Sequencing in Acute Myeloid Leukemia and Myelodysplastic Syndromes. The Journal of Molecular Diagnostics : Jmd. PMID 26331834 DOI: 10.1016/J.Jmoldx.2015.06.004 |
0.431 |
|
| 2015 |
Goyal L, Govindan A, Sheth RA, Nardi V, Blaszkowsky LS, Faris JE, Clark JW, Ryan DP, Kwak EL, Allen JN, Murphy JE, Saha SK, Hong TS, Wo JY, Ferrone CR, ... ... Borger DR, et al. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma. The Oncologist. PMID 26245674 DOI: 10.1634/Theoncologist.2015-0210 |
0.405 |
|
| 2015 |
Dong F, Kojiro S, Borger DR, Growdon WB, Oliva E. Squamous Cell Carcinoma of the Vulva: A Subclassification of 97 Cases by Clinicopathologic, Immunohistochemical, and Molecular Features (p16, p53, and EGFR). The American Journal of Surgical Pathology. 39: 1045-53. PMID 26171917 DOI: 10.1097/Pas.0000000000000454 |
0.303 |
|
| 2015 |
O'Donnell E, Mahindra A, Yee AJ, Nardi V, Birrer N, Horick N, Borger D, Finkelstein D, Iafrate JA, Raje N. Clinical Grade "SNaPshot" Genetic Mutation Profiling in Multiple Myeloma. Ebiomedicine. 2: 71-3. PMID 26137536 DOI: 10.1016/J.Ebiom.2014.11.008 |
0.439 |
|
| 2015 |
Niederst MJ, Sequist LV, Poirier JT, Mermel CH, Lockerman EL, Garcia AR, Katayama R, Costa C, Ross KN, Moran T, Howe E, Fulton LE, Mulvey HE, Bernardo LA, Mohamoud F, ... ... Borger DR, et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nature Communications. 6: 6377. PMID 25758528 DOI: 10.1038/Ncomms7377 |
0.384 |
|
| 2015 |
Moy AP, Shahid M, Ferrone CR, Borger DR, Zhu AX, Ting D, Deshpande V. Microsatellite instability in gallbladder carcinoma. Virchows Archiv : An International Journal of Pathology. 466: 393-402. PMID 25680569 DOI: 10.1007/S00428-015-1720-0 |
0.393 |
|
| 2015 |
Growdon WB, Groeneweg J, Byron V, DiGloria C, Borger DR, Tambouret R, Foster R, Chenna A, Sperinde J, Winslow J, Rueda BR. HER2 over-expressing high grade endometrial cancer expresses high levels of p95HER2 variant. Gynecologic Oncology. 137: 160-6. PMID 25602714 DOI: 10.1016/J.Ygyno.2015.01.533 |
0.371 |
|
| 2015 |
Kwak EL, Lennerz JK, Szymonifka J, Corcoran RB, Clark JW, Russo AL, Borger DR, Blaszkowsky LS, Dias LE, Faris JE, Murphy JE, Fidias P, Lennes IT, Azzoli CG, Gainor JF, et al. Clinical characteristics and treatment outcomes of patients with metastatic, MET-amplified esophagogastric cancers. Journal of Clinical Oncology. 33: 4043-4043. DOI: 10.1200/Jco.2015.33.15_Suppl.4043 |
0.374 |
|
| 2015 |
Brunner AM, Neuberg DS, Wander SA, Sadrzadeh H, Ballen KK, Amrein PC, Hobbs GS, Chen Y, Perry AM, Joseph C, Burke ME, Ramos AY, Silver R, Galinsky I, Adamia S, ... Borger D, et al. Use of 2HG Levels in the Serum, Urine, or Bone Marrow to Predict IDH Mutations in Adults with Acute Myeloid Leukemia Blood. 126: 2597-2597. DOI: 10.1182/Blood.V126.23.2597.2597 |
0.365 |
|
| 2015 |
Micalizzi DS, Juric D, Niemierko A, Reynolds KL, Borger D, Vora SR, Isakoff SJ, Moy B, Ellisen LW, Bardia A. Abstract P1-13-03: Association of PIK3CA mutation with clinical response to specific endocrine therapies in metastatic hormone receptor positive (HR+) breast cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-P1-13-03 |
0.462 |
|
| 2015 |
Hernandez SF, DiGloria C, Groeneweg J, Borger D, Foster R, Rueda B, Growdon W. Abstract 658: Phosphorylated HER3 levels associated with trastuzumab resistance inHER2gene amplified uterine serous carcinoma xenograft tumors Cancer Research. 75: 658-658. DOI: 10.1158/1538-7445.Am2015-658 |
0.392 |
|
| 2015 |
Zheng Z, Shetty R, Liebers M, Cambry JL, Bernardo LA, Borger D, Le LP, Iafrate JA. Abstract 4895: A one-tube assay for simultaneous detection of gene mutation, fusion, copy number alteration and expression Cancer Research. 75: 4895-4895. DOI: 10.1158/1538-7445.Am2015-4895 |
0.411 |
|
| 2015 |
Rueda B, Digloria C, Hall T, Foster R, Borger D, Growdon W. Abstract 2666: PI3K inhibition induces homologous repair defects in endometrioid endometrial cancer patient derived xenografts leading to synergistic anti-tumor activity with PARP inhibitors Cancer Research. 75: 2666-2666. DOI: 10.1158/1538-7445.Am2015-2666 |
0.454 |
|
| 2015 |
Growdon W, Hernandez SF, Chisholm S, Borger D, Foster R, Rueda BR. Ridaforolimus improves the anti-tumor activity of dual HER2 blockade in uterine serous carcinoma in vivo models with HER2 gene amplification and a gain of function mutation in PIK3CA Gynecologic Oncology. 139: 597. DOI: 10.1016/J.Ygyno.2015.09.062 |
0.411 |
|
| 2015 |
Kamran S, Russo A, Borger D, Szymonifka J, Kwak E, Clark J, Blaszkowsky L, Ryan D, Allen J, Wo J, Zhu A, Iafrate A, Haigis K, Hong T. Influence of Body Mass Index (BMI) on Colorectal Cancer Mutation Status International Journal of Radiation Oncology*Biology*Physics. 93: E155. DOI: 10.1016/J.Ijrobp.2015.07.943 |
0.352 |
|
| 2014 |
Groeneweg JW, Hernandez SF, Byron VF, DiGloria CM, Lopez H, Scialabba V, Kim M, Zhang L, Borger DR, Tambouret R, Foster R, Rueda BR, Growdon WB. Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 6517-28. PMID 25294905 DOI: 10.1158/1078-0432.Ccr-14-1647 |
0.383 |
|
| 2014 |
Hezel AF, Noel MS, Allen JN, Abrams TA, Yurgelun M, Faris JE, Goyal L, Clark JW, Blaszkowsky LS, Murphy JE, Zheng H, Khorana AA, Connolly GC, Hyrien O, Baran A, ... ... Borger DR, et al. Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer. British Journal of Cancer. 111: 430-6. PMID 24960403 DOI: 10.1038/Bjc.2014.343 |
0.384 |
|
| 2014 |
Zhu AX, Borger DR, Kim Y, Cosgrove D, Ejaz A, Alexandrescu S, Groeschl RT, Deshpande V, Lindberg JM, Ferrone C, Sempoux C, Yau T, Poon R, Popescu I, Bauer TW, et al. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets. Annals of Surgical Oncology. 21: 3827-34. PMID 24889489 DOI: 10.1245/S10434-014-3828-X |
0.399 |
|
| 2014 |
Dienstmann R, Dong F, Borger D, Dias-Santagata D, Ellisen LW, Le LP, Iafrate AJ. Standardized decision support in next generation sequencing reports of somatic cancer variants. Molecular Oncology. 8: 859-73. PMID 24768039 DOI: 10.1016/J.Molonc.2014.03.021 |
0.373 |
|
| 2014 |
Fathi AT, Sadrzadeh H, Comander AH, Higgins MJ, Bardia A, Perry A, Burke M, Silver R, Matulis CR, Straley KS, Yen KE, Agresta S, Kim H, Schenkein DP, Borger DR. Isocitrate dehydrogenase 1 (IDH1) mutation in breast adenocarcinoma is associated with elevated levels of serum and urine 2-hydroxyglutarate. The Oncologist. 19: 602-7. PMID 24760710 DOI: 10.1634/Theoncologist.2013-0417 |
0.441 |
|
| 2014 |
Wakimoto H, Tanaka S, Curry WT, Loebel F, Zhao D, Tateishi K, Chen J, Klofas LK, Lelic N, Kim JC, Dias-Santagata D, Ellisen LW, Borger DR, Fendt SM, Vander Heiden MG, et al. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2898-909. PMID 24714777 DOI: 10.1158/1078-0432.Ccr-13-3052 |
0.413 |
|
| 2014 |
Richter JM, Pino MS, Austin TR, Campbell E, Szymonifka J, Russo AL, Hong TS, Borger D, Iafrate AJ, Chung DC. Genetic mechanisms in interval colon cancers. Digestive Diseases and Sciences. 59: 2255-63. PMID 24705641 DOI: 10.1007/S10620-014-3134-2 |
0.331 |
|
| 2014 |
Guo S, Lopez-Marquez H, Fan KC, Choy E, Cote G, Harmon D, Nielsen GP, Yang C, Zhang C, Mankin H, Hornicek FJ, Borger DR, Duan Z. Synergistic effects of targeted PI3K signaling inhibition and chemotherapy in liposarcoma. Plos One. 9: e93996. PMID 24695632 DOI: 10.1371/Journal.Pone.0093996 |
0.471 |
|
| 2014 |
Bradford LS, Rauh-Hain A, Clark RM, Groeneweg JW, Zhang L, Borger D, Zukerberg LR, Growdon WB, Foster R, Rueda BR. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer. Gynecologic Oncology. 133: 346-52. PMID 24561032 DOI: 10.1016/J.Ygyno.2014.02.022 |
0.434 |
|
| 2014 |
Russo AL, Borger DR, Szymonifka J, Ryan DP, Wo JY, Blaszkowsky LS, Kwak EL, Allen JN, Wadlow RC, Zhu AX, Murphy JE, Faris JE, Dias-Santagata D, Haigis KM, Ellisen LW, et al. Mutational analysis and clinical correlation of metastatic colorectal cancer. Cancer. 120: 1482-90. PMID 24500602 DOI: 10.1002/Cncr.28599 |
0.474 |
|
| 2014 |
Borger DR, Goyal L, Yau T, Poon RT, Ancukiewicz M, Deshpande V, Christiani DC, Liebman HM, Yang H, Kim H, Yen K, Faris JE, Iafrate AJ, Kwak EL, Clark JW, et al. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1884-90. PMID 24478380 DOI: 10.1158/1078-0432.Ccr-13-2649 |
0.435 |
|
| 2014 |
Blaszkowsky LS, Ryan DP, Szymonifka J, Borger DR, Zhu AX, Clark JW, Kwak EL, Mamon HJ, Allen JN, Vasudev E, Shellito PC, Cusack JC, Berger DL, Hong TS. Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 121-6. PMID 24356623 DOI: 10.1093/Annonc/Mdt516 |
0.312 |
|
| 2014 |
Akhavanfard S, Vargas SO, Han M, Nitta M, Chang CB, Le LP, Fazlollahi L, Nguyen Q, Ma Y, Cosper A, Dias-Santagata D, Han JY, Bergethon K, Borger DR, Ellisen LW, et al. Inactivation of the tumor suppressor WTX in a subset of pediatric tumors. Genes, Chromosomes & Cancer. 53: 67-77. PMID 24249259 DOI: 10.1002/Gcc.22118 |
0.358 |
|
| 2014 |
Cipriani NA, Letovanec I, Hornicek FJ, Mullen JT, Duan Z, Borger DR, Nielsen GP. BRAF mutation in 'sarcomas': a possible method to detect de-differentiated melanomas. Histopathology. 64: 639-46. PMID 24117833 DOI: 10.1111/His.12305 |
0.418 |
|
| 2014 |
Russo AL, Ryan DP, Borger DR, Wo JY, Szymonifka J, Liang WY, Kwak EL, Blaszkowsky LS, Clark JW, Allen JN, Zhu AX, Berger DL, Cusack JC, Mamon HJ, Haigis KM, et al. Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer. Journal of Gastrointestinal Cancer. 45: 34-9. PMID 24006244 DOI: 10.1007/S12029-013-9546-Y |
0.466 |
|
| 2014 |
Noel MS, Allen JN, Abrams TA, Yurgelun M, Faris JE, Goyal L, Clark JW, Blaszkowsky LS, Murphy JE, Zheng H, Khorana AA, Connolly GC, Hyrien O, Ng K, Borger DR, et al. A single-arm phase II trial of gemcitabine, oxaliplatin, and panitumumab in KRAS wild-type advanced biliary tract cancer. Journal of Clinical Oncology. 32: 255-255. DOI: 10.1200/Jco.2014.32.3_Suppl.255 |
0.378 |
|
| 2014 |
Pawlik TM, Borger DR, Kim Y, Cosgrove D, Alexandrescu S, Groeschl RT, Deshpande V, Lindberg JM, Ferrone C, Sempoux C, Popescu I, Bauer TW, Gamblin TC, Gigot JF, Anders R, et al. Genomic profiling of intrahepatic cholangiocarcinoma: Refining prognostic determinants and identifying therapeutic targets. Journal of Clinical Oncology. 32: 210-210. DOI: 10.1200/Jco.2014.32.3_Suppl.210 |
0.472 |
|
| 2014 |
O'Donnell E, Mahindra AK, Yee AJ, Birrer N, Horick N, Finkelstein DM, Borger DR, Iafrate AJ, Raje NS. Clinical grade SNaPshot genetic mutation profiling in multiple myeloma. Journal of Clinical Oncology. 32. DOI: 10.1200/Jco.2014.32.15_Suppl.E19571 |
0.48 |
|
| 2014 |
Faris JE, Borger DR, Castillo CF, Clark JW, Blaszkowsky LS, Zhu AX, Allen JN, Murphy JE, Ferrone C, Goyal L, Bardeesy N, Duda GD, Zheng H, Ting DT, Kwak EL, et al. Effect of molecular genotyping to predict outcomes in patients with metastatic pancreatic cancer. Journal of Clinical Oncology. 32: 4128-4128. DOI: 10.1200/Jco.2014.32.15_Suppl.4128 |
0.448 |
|
| 2014 |
Wakimoto H, Tanaka S, Curry WT, Loebel F, Zhao D, Tateishi K, Chen J, Klofas LK, Lelic N, Kim JC, Dias-Santagata D, Ellisen LW, Borger DR, Fendt S, Heiden MV, et al. Targetable signaling pathway mutations and progression of IDH-mutant glioma. Journal of Clinical Oncology. 32: 2061-2061. DOI: 10.1200/Jco.2014.32.15_Suppl.2061 |
0.416 |
|
| 2014 |
Brunner AM, Wander SA, Neuberg D, Sadrzadeh H, Ballen KK, Amrein PC, Attar EC, Chen Y, Perry AM, Burke M, Silver R, Adamia S, Yen K, Yang H, Straley K, ... ... Borger DR, et al. Diagnostic Features and 2-Hydroxyglutarate (2-HG) Levels Among Acute Myeloid Leukemia (AML) Patients with and without Isocitrate Dehydrogenase (IDH) Mutations Blood. 124: 1045-1045. DOI: 10.1182/Blood.V124.21.1045.1045 |
0.391 |
|
| 2014 |
Niederst MJ, Sequist LV, Lockerman EL, Garcia AR, Costa C, Mohamoud F, Borger DR, Shioda T, Getz G, Iafrate AJ, Mino-Kenudson M, Engelman JA. Abstract 955: Transformation from NSCLC to SCLC in EGFR mutant lung cancers with acquired resistance to EGFR inhibitors Cancer Research. 74: 955-955. DOI: 10.1158/1538-7445.Am2014-955 |
0.406 |
|
| 2014 |
Dienstmann R, Dong F, Borger D, Santagata DD, Ellisen LW, Le LP, Iafrate AJ. Abstract 4260: Standardized decision support in next-generation sequencing (NGS) reports of somatic cancer variants Cancer Research. 74: 4260-4260. DOI: 10.1158/1538-7445.Am2014-4260 |
0.422 |
|
| 2014 |
Growdon WB, Groeneweg JW, Byron VF, Hernandez SF, Borger DR, Tambouret R, Schorge JO, Carmen MGD, Foster R, Rueda BR. Dual HER2 targeting impedes growth of HER2 gene-amplified uterine papillary serous carcinoma xenografts Gynecologic Oncology. 133: 117. DOI: 10.1016/J.Ygyno.2014.03.308 |
0.373 |
|
| 2013 |
Juric D, Isakoff SJ, Borger DR, Dias-Santagata D, Higgins MJ, Iafrate AJ, Flaherty K, Moy B, Ellisen LW. Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 145. PMID 28136532 DOI: 10.1200/Jco.2013.31.15_Suppl.533 |
0.387 |
|
| 2013 |
Chi AS, Batchelor TT, Yang D, Dias-Santagata D, Borger DR, Ellisen LW, Iafrate AJ, Louis DN. BRAF V600E mutation identifies a subset of low-grade diffusely infiltrating gliomas in adults. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: e233-6. PMID 23547069 DOI: 10.1200/Jco.2012.46.0220 |
0.345 |
|
| 2013 |
Nardi V, Sadow PM, Juric D, Zhao D, Cosper AK, Bergethon K, Scialabba VL, Batten JM, Borger DR, Iafrate AJ, Heist RS, Lawrence DP, Flaherty KT, Bendell JC, Deschler D, et al. Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 480-90. PMID 23186780 DOI: 10.1158/1078-0432.Ccr-12-1842 |
0.479 |
|
| 2013 |
Russo AL, Ryan DP, Borger DR, Wo JY, Szymonifka J, Kwak EL, Blaszkowsky LS, Clark JW, Allen JN, Zhu AX, Berger DL, Cusack JC, Haigis KM, Hong TS. Mutational analysis of locally advanced rectal cancer and response to neoadjuvant chemoradiation. Journal of Clinical Oncology. 31: 449-449. DOI: 10.1200/Jco.2013.31.4_Suppl.449 |
0.475 |
|
| 2013 |
Murphy JE, Russo AL, Szymonifka J, Kwak EL, Allen JN, Zhu AX, Blaszkowsky LS, Clark JW, Ryan DP, Hong TS, Borger DR. DNA mutation frequencies in metastatic small bowel adenocarcinoma (mSBA) in comparison to gastric (mGC), colon (mCC), and rectal cancer (mRC): Continuum or cutpoint? Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.E14636 |
0.359 |
|
| 2013 |
Bradford LS, Rauh-Hain JA, Clark RM, Groeneweg JW, Zhang L, DiGloria CM, Borger DR, Growdon WB, Schorge JO, Foster R, Rueda BR. Targeting the PI3K signaling cascade in PIK3CA mutated endometrial cancer in a primary human xenograft model. Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.E13564 |
0.465 |
|
| 2013 |
Goyal L, Borger DR, Yau T, Poon RTP, Ancukiewicz M, Christiani DC, Liebman HM, Yen K, Straley K, Agresta SV, Faris JE, Kwak EL, Clark JW, Ryan DP, Tanabe K, et al. Circulating oncometabolite 2-hydroxyglutarate (2HG) as a potential surrogate biomarker in patients with isocitrate dehydrogenase mutant (IDHm) intrahepatic cholangiocarcinoma (ICC). Journal of Clinical Oncology. 31: 4125-4125. DOI: 10.1200/Jco.2013.31.15_Suppl.4125 |
0.324 |
|
| 2013 |
Hong TS, Deshpande V, Ancukiewicz M, Yeap BY, Borger DR, Wo JY, Boucher Y, Kwak EL, Clark JW, Zhu AX, Blaszkowsky LS, Mamon HJ, Jain RK, Ryan DP, DeLaney TF, et al. Genetic, tissue, and plasma biomarkers of outcomes from a prospective study of neoadjuvant short course proton-based chemoradiation for resectable pancreatic ductal adenocarcinoma (PDAC). Journal of Clinical Oncology. 31: 4047-4047. DOI: 10.1200/Jco.2013.31.15_Suppl.4047 |
0.304 |
|
| 2013 |
Tanaka S, Batchelor T, Iafrate AJ, Dias-Santagata D, Borger DR, Ellisen LW, Yang D, Louis DN, Cahill DP, Chi AS. Association of PIK3CA-activating mutations with more disseminated disease at presentation and earlier recurrence in glioblastoma. Journal of Clinical Oncology. 31: 2029-2029. DOI: 10.1200/Jco.2013.31.15_Suppl.2029 |
0.44 |
|
| 2013 |
Niederst MJ, Sequist LV, Lockerman EL, Costa C, Borger DR, Mino-Kenudson M, Iafrate AJ, Engelman JA. Abstract A87: Overcoming NSCLC to SCLC transformation as a resistance mechanism in EGFR mutant lung cancer. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-A87 |
0.399 |
|
| 2013 |
Growdon W, Johnson T, Byron V, Foster R, Tambouret R, Schorge J, Penson R, Rueda B, Borger D. A uterine-specific PIK3CA and PTEN dual mutation signature is associated with poor prognosis Gynecologic Oncology. 130. DOI: 10.1016/J.Ygyno.2013.04.275 |
0.417 |
|
| 2013 |
Russo AL, Kwak EL, Borger DR, Szymonifka J, Mullen JT, Zhu AX, Blaszkowsky LS, Wo JY, Ryan DP, Hong TS. Mutational Profile of Gastroesophageal Cancer Compared to Gastric and Esophageal Cancers International Journal of Radiation Oncology Biology Physics. 87. DOI: 10.1016/J.Ijrobp.2013.06.221 |
0.382 |
|
| 2012 |
Fathi AT, Sadrzadeh H, Borger DR, Ballen KK, Amrein PC, Attar EC, Foster J, Burke M, Lopez HU, Matulis CR, Edmonds KM, Iafrate AJ, Straley KS, Yen KE, Agresta S, et al. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood. 120: 4649-52. PMID 23074281 DOI: 10.1182/Blood-2012-06-438267 |
0.353 |
|
| 2012 |
Chi AS, Batchelor TT, Dias-Santagata D, Borger D, Stiles CD, Wang DL, Curry WT, Wen PY, Ligon KL, Ellisen L, Louis DN, Iafrate AJ. Prospective, high-throughput molecular profiling of human gliomas. Journal of Neuro-Oncology. 110: 89-98. PMID 22821383 DOI: 10.1007/S11060-012-0938-9 |
0.462 |
|
| 2012 |
Horowitz NS, Olawaiye AB, Borger DR, Growdon WB, Krasner CN, Matulonis UA, Liu JF, Lee J, Brard L, Dizon DS. Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva Gynecologic Oncology. 127: 141-146. PMID 22750258 DOI: 10.1016/J.Ygyno.2012.06.028 |
0.379 |
|
| 2012 |
Borger DR, Zhu AX. IDH mutations: new genetic signatures in cholangiocarcinoma and therapeutic implications. Expert Review of Anticancer Therapy. 12: 543-6. PMID 22594888 DOI: 10.1586/Era.12.32 |
0.379 |
|
| 2012 |
Nardi V, Song Y, Santamaria-Barria JA, Cosper AK, Lam Q, Faber AC, Boland GM, Yeap BY, Bergethon K, Scialabba VL, Tsao H, Settleman J, Ryan DP, Borger DR, Bhan AK, et al. Activation of PI3K signaling in Merkel cell carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 1227-36. PMID 22261808 DOI: 10.1158/1078-0432.Ccr-11-2308 |
0.349 |
|
| 2012 |
Borger DR, Tanabe KK, Fan KC, Lopez HU, Fantin VR, Straley KS, Schenkein DP, Hezel AF, Ancukiewicz M, Liebman HM, Kwak EL, Clark JW, Ryan DP, Deshpande V, Dias-Santagata D, et al. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. The Oncologist. 17: 72-9. PMID 22180306 DOI: 10.1634/Theoncologist.2011-0386 |
0.51 |
|
| 2012 |
Fathi AT, Abdel-Wahab OI, Sadrzadeh H, Foster J, Burke M, Borger DR, Iafrate AJ, Adamia S, Liu S, Ballen KK, Amrein PC, Attar EC, Straley K, Yen K, Schenkein DP, et al. Prospective evaluation of serial 2-hydroxyglutarate in acute myeloid leukemia (AML) to determine response to therapy and predict relapse. Journal of Clinical Oncology. 30: 6606-6606. DOI: 10.1200/Jco.2012.30.15_Suppl.6606 |
0.36 |
|
| 2012 |
Sales E, Penson RT, Sullivan LA, Borger DR, Krasner CN, Goodman A, Carmen MGd, Growdon WB, Schorge JO, Boruta DM, Birrer MJ. A snapshot of potentially personalized care: Molecular diagnostics in gynecologic cancer. Journal of Clinical Oncology. 30: 5029-5029. DOI: 10.1200/Jco.2012.30.15_Suppl.5029 |
0.505 |
|
| 2012 |
Mahindra A, Dias-Santagata D, Borger D, Santo L, Scullen TA, Yee A, Eda H, Cirstea D, Iafrate AJ, Raje N. Mutational Profiling of Multiple Myeloma Bone Marrow Aspirates As a Clinical Tool for Personalized Treatment of Myeloma Blood. 120: 3990-3990. DOI: 10.1182/Blood.V120.21.3990.3990 |
0.467 |
|
| 2012 |
Bardia A, Dias-Santagata D, Isakoff SJ, Borger DR, Juric D, Higgins MJ, Moy B, Goss PE, Baselga J, Iafrate AJ, Ellisen LW. Abstract 962: Multiplexed mutational profiling of breast tumor as an efficient clinical tool for personalized breast cancer treatment Cancer Research. 72: 962-962. DOI: 10.1158/1538-7445.Am2012-962 |
0.479 |
|
| 2012 |
Groeneweg JW, Tambouret RH, Borger DR, Foster R, Rueda BR, Growdon WB. Abstract 4556: Epidermal growth factor signaling alterations in uterine papillary serous carcinoma (UPSC) associate with survival Cancer Research. 72: 4556-4556. DOI: 10.1158/1538-7445.Am2012-4556 |
0.41 |
|
| 2012 |
Bradford L, Zhang L, Groeneweg J, Borger D, Engelman J, Foster R, Growdon W, Schorge J, Rueda B. Inhibition of PI3K–AKT signaling precludes endometrial cancer growth in a primary human xenograft model harboring an oncogenic PIK3CA mutation Gynecologic Oncology. 125. DOI: 10.1016/J.Ygyno.2011.12.313 |
0.408 |
|
| 2011 |
Sequist LV, Heist RS, Shaw AT, Fidias P, Temel JS, Lennes IT, Bast E, Waltman BA, Lanuti M, Muzikansky A, Mino-Kenudson M, Iafrate AJ, Borger DR, Dias-Santagata D, Engelman JA. SNaPshot genotyping of non-small cell lung cancers (NSCLC) in clinical practice. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7518. PMID 28023280 DOI: 10.1200/Jco.2011.29.15_Suppl.7518 |
0.351 |
|
| 2011 |
Wirth LJ, Nardi V, Juric D, Cosper AK, Bergethon K, Scialabba V, Borger DR, Iafrate AJ, Ellisen LW, Deschler D, Zhao D, Sadow PM, Dias-Santagata D. Detection of novel genetic aberrations in salivary duct carcinoma (SDC) by SNaPshot analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 5579. PMID 28022120 DOI: 10.1200/Jco.2011.29.15_Suppl.5579 |
0.409 |
|
| 2011 |
Yee AJ, Raz T, Amzallag A, Lipson D, Giladi E, Lopez H, Borger DR, Mino-Kenudson M, Thompson JF, Iafrate AJ, Milos P, Haber DA, Ramaswamy S. Single molecule RNA sequencing of formalin-fixed paraffin-embedded tissue derived from patients with lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 10550. PMID 28021919 DOI: 10.1200/Jco.2011.29.15_Suppl.10550 |
0.317 |
|
| 2011 |
Isakoff SJ, Goss PE, Mayer EL, Traina TA, Carey LA, Krag K, Rugo HS, Liu MC, Stearns V, Come SE, Borger DR, Quadrino CA, Finkelstein D, Garber JE, Ryan PD, et al. TBCRC009: A multicenter phase II study of cisplatin or carboplatin for metastatic triple-negative breast cancer and evaluation of p63/p73 as a biomarker of response. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 1025. PMID 28020734 DOI: 10.1200/Jco.2011.29.15_Suppl.1025 |
0.311 |
|
| 2011 |
Russo AL, Borger DR, Ryan DP, Fan KC, Lopez H, Scialabba V, Blaszkowsky LS, Kwak EL, Clark JW, Allen JN, Wadlow RC, Zhu AX, Wang R, Dias-Santagata D, Hong TS, et al. Mutational analysis and clinical correlation of 185 consecutive metastatic colorectal patients: Similarities and differences between colon and rectal patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 3536. PMID 28020316 DOI: 10.1200/Jco.2011.29.15_Suppl.3536 |
0.464 |
|
| 2011 |
Ryan RJ, Nitta M, Borger D, Zukerberg LR, Ferry JA, Harris NL, Iafrate AJ, Bernstein BE, Sohani AR, Le LP. EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. Plos One. 6: e28585. PMID 22194861 DOI: 10.1371/Journal.Pone.0028585 |
0.402 |
|
| 2011 |
McCann CK, Growdon WB, Kulkarni-Datar K, Curley MD, Friel AM, Proctor JL, Sheikh H, Deyneko I, Ferguson JA, Vathipadiekal V, Birrer MJ, Borger DR, Mohapatra G, Zukerberg LR, Foster R, et al. Inhibition of Hedgehog signaling antagonizes serous ovarian cancer growth in a primary xenograft model. Plos One. 6: e28077. PMID 22140510 DOI: 10.1371/Journal.Pone.0028077 |
0.39 |
|
| 2011 |
Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, Lennes IT, Digumarthy S, Waltman BA, Bast E, Tammireddy S, Morrissey L, Muzikansky A, Goldberg SB, Gainor J, ... ... Borger DR, et al. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 22: 2616-24. PMID 22071650 DOI: 10.1093/Annonc/Mdr489 |
0.333 |
|
| 2011 |
Dias-Santagata D, Lam Q, Vernovsky K, Vena N, Lennerz JK, Borger DR, Batchelor TT, Ligon KL, Iafrate AJ, Ligon AH, Louis DN, Santagata S. BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications. Plos One. 6: e17948. PMID 21479234 DOI: 10.1371/Journal.Pone.0017948 |
0.483 |
|
| 2011 |
Su Z, Dias-Santagata D, Duke M, Hutchinson K, Lin YL, Borger DR, Chung CH, Massion PP, Vnencak-Jones CL, Iafrate AJ, Pao W. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. The Journal of Molecular Diagnostics : Jmd. 13: 74-84. PMID 21227397 DOI: 10.1016/J.Jmoldx.2010.11.010 |
0.47 |
|
| 2011 |
Growdon WB, Roussel BN, Scialabba VL, Foster R, Dias-Santagata D, Iafrate AJ, Ellisen LW, Tambouret RH, Rueda BR, Borger DR. Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin. Gynecologic Oncology. 121: 212-7. PMID 21168197 DOI: 10.1016/J.Ygyno.2010.11.039 |
0.487 |
|
| 2011 |
Nardi V, Song YC, Cosper AK, Lam Q, Barria JAS, Boland GM, Yeap B, Bergethon K, Scialabba VL, Settleman J, Ryan DP, Borger DR, Hoang MP, Bhan AK, Iafrate AJ, et al. Abstract 2210: Activation of PI3K in Merkel cell carcinoma Cancer Research. 71: 2210-2210. DOI: 10.1158/1538-7445.Am2011-2210 |
0.519 |
|
| 2011 |
Growdon W, Garrett L, Rousel B, Scialabba V, Ellisen L, Dias-Santagata D, Foster R, Tambouret R, Rueda B, Borger D. Activating PIK3CA and RAS mutations identified exclusively in carcinosarcomas of uterine origin Gynecologic Oncology. 120. DOI: 10.1016/J.Ygyno.2010.12.104 |
0.356 |
|
| 2010 |
Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, Gray JE, Iafrate AJ, Katayama R, Hafeez N, Sweeney J, Walker JR, Fritz C, Ross RW, Grayzel D, ... ... Borger DR, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 4953-60. PMID 20940188 DOI: 10.1200/Jco.2010.30.8338 |
0.331 |
|
| 2010 |
Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, Stubbs H, McDermott U, Settleman J, Kwak EL, Clark JW, Isakoff SJ, Sequist LV, Engelman JA, Lynch TJ, ... ... Borger DR, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. Embo Molecular Medicine. 2: 146-58. PMID 20432502 DOI: 10.1002/Emmm.201000070 |
0.45 |
|
| 2010 |
Kalinsky K, Lee SJ, Lawrence DP, Iafrate AJ, Borger DR, Averbook BJ, Tarhini AA, Kirkwood JM. A phase II trial of dasatinib in patients with unresectable locally advanced or stage IV mucosal, acral, and solar melanomas: An Eastern Cooperative Oncology Group study (E2607). Journal of Clinical Oncology. 28: 8522-8522. DOI: 10.1200/Jco.2012.30.15_Suppl.8522 |
0.372 |
|
| 2010 |
Waltman BA, Dias-Santagata D, Cosper AK, Mino-Kenudson M, Borger DR, Fidias P, Shaw AT, Iafrate AJ, Engelman JA, Sequist LV. SNaPshot multigene assay to detect mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). Journal of Clinical Oncology. 28: 7554-7554. DOI: 10.1200/Jco.2010.28.15_Suppl.7554 |
0.34 |
|
| 2010 |
Sequist LV, Natale RB, Senzer NN, Martins R, Lilenbaum R, Gray JE, Borger DR, Paez G, Grayzel DS, Gettinger SN. Association between anaplastic lymphoma kinase rearrangements (rALK) and the clinical activity of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 28: 7517-7517. DOI: 10.1200/Jco.2010.28.15_Suppl.7517 |
0.351 |
|
| 2008 |
Growdon WB, Boisvert SL, Akhavanfard S, Oliva E, Dias-Santagata DC, Kojiro S, Horowitz NS, Iafrate AJ, Borger DR, Rueda BR. Decreased survival in EGFR gene amplified vulvar carcinoma. Gynecologic Oncology. 111: 289-97. PMID 18768215 DOI: 10.1016/J.Ygyno.2008.07.038 |
0.38 |
|
| 2000 |
Mi Y, Borger DR, Fernandes PR, Pirisi L, Creek KE. Loss of transforming growth factor-beta (TGF-beta) receptor type I mediates TGF-beta resistance in human papillomavirus type 16-transformed human keratinocytes at late stages of in vitro progression. Virology. 270: 408-16. PMID 10793000 DOI: 10.1006/Viro.2000.0283 |
0.562 |
|
| 2000 |
Borger DR, Mi Y, Geslani G, Zyzak LL, Batova A, Engin TS, Pirisi L, Creek KE. Retinoic acid resistance at late stages of human papillomavirus type 16-mediated transformation of human keratinocytes arises despite intact retinoid signaling and is due to a loss of sensitivity to transforming growth factor-beta. Virology. 270: 397-407. PMID 10792999 DOI: 10.1006/Viro.2000.0282 |
0.574 |
|
| Show low-probability matches. |